The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
CALM study: A phase II study of an intratumorally delivered oncolytic immunotherapeutic agent, coxsackievirus A21, in patients with stage IIIc and stage IV malignant melanoma.
Robert Hans Ingemar Andtbacka
Research Funding - Viralytics
Brendan D. Curti
No relevant relationships to disclose
Howard Kaufman
No relevant relationships to disclose
Gregory A. Daniels
No relevant relationships to disclose
John J. Nemunaitis
No relevant relationships to disclose
Lynn E. Spitler
No relevant relationships to disclose
Sigrun Hallmeyer
No relevant relationships to disclose
Jose Lutzky
No relevant relationships to disclose
Stephen Schultz
No relevant relationships to disclose
Eric D. Whitman
No relevant relationships to disclose
Karl Zhou
No relevant relationships to disclose
Jeffrey Ira Weisberg
Consultant or Advisory Role - Viralytics
Stock Ownership - Viralytics
Other Remuneration - Viralytics
Darren Shafren
Employment or Leadership Position - Viralytics
Consultant or Advisory Role - Viralytics
Stock Ownership - Viralytics
Research Funding - Viralytics (I)
Other Remuneration - Viralytics